Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Niagen Bioscience Inc (NAGE)

Niagen Bioscience Inc (NAGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 342,742
  • Shares Outstanding, K 80,080
  • Annual Sales, $ 129,420 K
  • Annual Income, $ 17,380 K
  • EBIT $ 14 M
  • EBITDA $ 15 M
  • 60-Month Beta 2.12
  • Price/Sales 2.60
  • Price/Cash Flow 20.71
  • Price/Book 4.38

Options Overview Details

View History
  • Implied Volatility 192.83% (+50.64%)
  • Historical Volatility 45.39%
  • IV Percentile 93%
  • IV Rank 18.98%
  • IV High 789.28% on 02/18/26
  • IV Low 53.07% on 06/27/25
  • Expected Move (DTE 17) 0.59 (13.36%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 12
  • Volume Avg (30-Day) 357
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 12,643
  • Open Int (30-Day) 13,969
  • Expected Range 3.80 to 4.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.06
  • Number of Estimates 2
  • High Estimate $0.08
  • Low Estimate $0.04
  • Prior Year $0.04
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.16 +6.01%
on 03/30/26
5.78 -23.70%
on 03/05/26
-0.64 (-12.67%)
since 02/27/26
3-Month
4.16 +6.01%
on 03/30/26
6.86 -35.76%
on 01/07/26
-2.23 (-33.58%)
since 12/26/25
52-Week
4.16 +6.01%
on 03/30/26
14.69 -69.98%
on 06/30/25
-2.36 (-34.86%)
since 03/28/25

Most Recent Stories

More News
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas

Niagen IV launches across Medi-Spa clinics on high-end cruise ships, expanding Niagen Plus’ footprint

OSW : 22.92 (+3.01%)
NAGE : 4.41 (+3.04%)
Niagen Bioscience Increases Share Repurchase Program to $20 Million

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors...

NAGE : 4.41 (+3.04%)
Niagen Bioscience to Present at the 38th Annual ROTH Conference

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will...

NAGE : 4.41 (+3.04%)
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies

By supporting investigator-initiated research worldwide, the program has helped establish Niagen Bioscience as a foundational force in advancing NAD+ understanding across the industry

NAGE : 4.41 (+3.04%)
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®

Launch expands Niagen ® into the growing skincare category through a limited-release model designed to generate consumer insights and inform future innovation

NAGE : 4.41 (+3.04%)
Niagen Bioscience: Q4 Earnings Snapshot

Niagen Bioscience: Q4 Earnings Snapshot

NAGE : 4.41 (+3.04%)
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

Net sales increased 30% year-over-year to $129.4 million in 2025 Gross margin increased 250 bps year-over-year to 64.3% in 2025 Net...

NAGE : 4.41 (+3.04%)
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END

AVAI : 0.3200 (+10.34%)
NAGE : 4.41 (+3.04%)
GERN : 1.4900 (+5.67%)
NTLA : 12.81 (+9.96%)
OCGN : 1.8150 (+3.71%)
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction

Divestiture streamlines operations and advances the Company’s strategy to fully exit non-core activities

NAGE : 4.41 (+3.04%)
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®

Patent strengthens Niagen Bioscience’s intellectual property moat in fast-growing NAD+-boosting IV and injectable delivery formats, supporting commercial expansion and deterring infringers

NAGE : 4.41 (+3.04%)

Business Summary

Niagen Bioscience Inc. is a nicotinamide adenine dinucleotide science and healthy-aging research company. Niagen Bioscience Inc., formerly known as ChromaDex Corp., is based in LOS ANGELES.

See More

Key Turning Points

3rd Resistance Point 4.47
2nd Resistance Point 4.39
1st Resistance Point 4.33
Last Price 4.41
1st Support Level 4.19
2nd Support Level 4.11
3rd Support Level 4.05

See More

52-Week High 14.69
Fibonacci 61.8% 10.67
Fibonacci 50% 9.42
Fibonacci 38.2% 8.18
Last Price 4.41
52-Week Low 4.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.